Defunct Company
Total Trials
20
As Lead Sponsor
13
As Collaborator
7
Total Enrollment
474
NCT02652910
Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma
Phase: Phase 1/2
Role: Collaborator
Start: Dec 31, 2015
Completion: Dec 31, 2019
NCT03110640
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
Phase: Phase 1
Start: Oct 1, 2016
Completion: Sep 30, 2021
NCT03093168
BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
Start: Feb 15, 2017
Completion: Feb 29, 2020
NCT04303520
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL
Start: May 3, 2018
Completion: Feb 28, 2021
NCT03706547
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
Start: Oct 30, 2018
Completion: Dec 31, 2021
NCT03720457
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
Role: Lead Sponsor
Start: Nov 13, 2018
Completion: Oct 31, 2023
NCT03879382
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES
Start: Feb 27, 2019
Completion: May 30, 2022
NCT03798509
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
Start: Mar 13, 2019
Completion: Jan 31, 2024
NCT03799913
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Phase: Early Phase 1
Start: Apr 10, 2019
Completion: Apr 30, 2022
NCT04003168
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
Start: Jul 1, 2019
Completion: Jul 31, 2024
NCT03943472
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Start: Jul 8, 2019
Completion: May 31, 2022
NCT03814447
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
Start: Aug 16, 2019
Completion: Jan 31, 2023
NCT05436223
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
Phase: Phase 2
Start: Aug 9, 2021
Completion: Aug 9, 2026
NCT06760260
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Start: Jan 26, 2022
Completion: Dec 31, 2026
NCT05302648
To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
Start: Feb 9, 2022
Completion: Dec 31, 2025
NCT05223686
To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.
Start: Feb 10, 2022
Completion: Mar 10, 2025
NCT05594797
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Start: Jul 12, 2022
Completion: Jul 31, 2027
NCT05651178
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
Start: Aug 12, 2022
Completion: Aug 31, 2025
NCT05651191
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
Start: Oct 21, 2022
Completion: Sep 30, 2025
NCT06045091
To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
Start: Jul 4, 2023
Completion: Sep 30, 2027